glp-1 drug news today 2025 obesity october Outlook for obesity in 2025: more than a transition year GLP-1 Market Trends and Global
Description
The HARMONY-7 trial showed similar rates of GI side effects across both the liraglutide and albiglutide groups
Emerging Evidence on GLP-1 Therapies and Atrial Fibrillation Risk Recent studies exploring the link between GLP-1 therapies and atrial fibrillation present mixed findings
Saxenda is sometimes prescribed off-label for metabolic dysfunction-associated steatohepatitis (MASH)
doi: 10.2174/0115734021398680251001102514 40
Although not fully clarified, the mechanism of action of GLP-1 RAs on fatty liver disease may be multifactorial
43% of adults who have diabetes say they have used GLP-1 medications
